Updates of Adjuvant Therapy in Pancreatic Cancer: Where Are We and Where Are We Going?

  • Jia Li Yale University School of Medicine. New Haven, CT, USA
  • Man Yee Merl Yale-New Haven Hospital. New Haven, CT, USA
  • John Chabot Columbia University. New York, NY, USA
  • Muhammad Wasif Saif Yale University School of Medicine. New Haven, CT, USA
Keywords: Chemotherapy, Adjuvant, gemcitabine, Immunotherapy, Pancreatic Neoplasms

Abstract

Pancreatic cancer represents the 4th leading cause of cancer deaths in the United States. Surgical resection remains the only potential curative approach. Current standard adjuvant therapy is gemcitabine monotherapy for 6 months. This year several trials investigated other combinations with or without molecular target agents, with or without concurrent radiation attempting to optimize adjuvant therapy. Several abstracts presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting are highlighted here and will be further discussed in this review article. Abstracts #4012, #4059, and TPS226 added immunotherapy to adjuvant treatment. Abstract #4034 demonstrated lack of efficacy by adding either cetuximab or bevacizumab to known adjuvant therapies. Abstract e14625 combined S-1 to gemcitabine and abstract #4113 demonstrated a positive correlation between symptoms and CA 19-9 levels with the length of survival.

Image: Yale-New Haven Hospital. New Haven, CT, USA.

Downloads

Download data is not yet available.

References

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77. [PMID 17227978]

Hardacre JM, Mulcahy MF, Talamonti M, Obel JC, Rocha Lima CS, Safran H, et al. Effect of hyperacute immunotherapy in addition to standard adjuvant therapy for resected pancreatic cancer on disease-free and overall survival: Preliminary analysis of phase II data. J Clin Oncol 2010; 28(15 Suppl):4059.

Marten A, Schmidt J, Debus J, Harig S, Lindel K, Klein J, et al. CapRI: Final results of the open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon-?2b (CRI) versus 5-FU alone for patients with resected pancreatic adenocarcinoma (PAC). J Clin Oncol 2010; 28(18 Suppl):LBA4012.

Picozzi VJ, Abrams RA, Traverso LW, O’Reilly EM, Greeno E, Martin RC, et al. ACOSOG Z05031: Report on a multicenter, phase II trial for adjuvant therapy of resected pancreatic cancer using cisplatin, 5- FU, and alpha-interferon. J Clin Oncol 2008; 26(15 Suppl):4505.

Whiting SH, Muscarella P, Rosemurgy A, Fisher WE, Richards DA, Harrell FE Jr, et al. A randomized, placebo-controlled, multicenter phase II adjuvant trial of the efficacy, immunogenicity, and safety of GI-4000 plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer with activating ras mutations. J Clin Oncol 2010; 28(15 Suppl):TPS226.

Berlin J, Catalano PJ, Feng Y, Lowy AM, Blackstock AW, Philip PA, et al. ECOG 2204: An intergroup randomized phase II study of cetuximab (Ce) or bevacizumab (B) in combination with gemcitabine (G) and in combination with capecitabine (Ca) and radiation (XRT) as adjuvant therapy (Adj Tx) for patients (pts) with completely resected pancreatic adenocarcinoma (PC). J Clin Oncol 2010; 28(15 Suppl):4034.

Ishii H, Ueno H, Kosuge T, Matsuyama Y, Saiura A, Nakao A, et al. A phase I/II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP-03). J Clin Oncol 2010; 28(Suppl):e14625.

Vaccaro V, Fleming JB, Wolff RA, Evans DB, Tamm EP, Crane CH, et al. Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. J Clin Oncol 2010; 28(15 Suppl):4113.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™). Pancreatic Adenocarcinoma. V.I.2010. Fort Washington, PA, USA.

Yale-New Haven Hospital. New Haven, CT, USA
Published
2010-07-05
How to Cite
LiJ., MerlM., ChabotJ., & SaifM. (2010). Updates of Adjuvant Therapy in Pancreatic Cancer: Where Are We and Where Are We Going?. JOP. Journal of the Pancreas, 11(4), 310-312. https://doi.org/10.6092/1590-8577/3610
Section
Highlights from the “2010 ASCO Annual Meeting”. Chicago, IL, USA. June 4-8, 2010

Most read articles by the same author(s)